BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33539620)

  • 21. [Treatment of superficial infantile hemangiomas with topical propranolol].
    Niu JN; Xu GQ; Lü RR; Huo R
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2013 Mar; 29(2):100-3. PubMed ID: 23772486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial.
    Zaher H; Rasheed H; Esmat S; Hegazy RA; Gawdat HI; Hegazy RA; El-Komy M; Abdelhalim DM
    Eur J Dermatol; 2013; 23(5):646-52. PubMed ID: 24135427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral propranolol for parotid infantile hemangiomas.
    Li G; Xu DP; Sun HL; Cheng C; Liu ZM; Xi SL; Wang XK
    J Craniofac Surg; 2015 Mar; 26(2):438-40. PubMed ID: 25692890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Propranolol therapy for infantile hemangioma: our experience.
    Zhang L; Wu HW; Yuan W; Zheng JW
    Drug Des Devel Ther; 2017; 11():1401-1408. PubMed ID: 28507428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A further experience of propranolol for severe infantile hemangiomas of the face: an observational study.
    Greco A; D'Erme AM; Zamma Gallarati B; Caputo R; de Martino M
    Dermatol Ther; 2014; 27(4):198-202. PubMed ID: 24548454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Our experience with propranolol for infantile hemangioma.
    Wu Y; Zhao P; Song W; Lu W; Dai T; Wang L
    Skin Res Technol; 2023 Apr; 29(4):e13310. PubMed ID: 37113082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outpatient treatment of infantile hemangiomas with propranolol: a prospective study.
    Betlloch-Mas I; Martínez-Miravete MT; Lucas-Costa A; Martin de Lara AI; Selva-Otalaurruchi J
    Actas Dermosifiliogr; 2012 Nov; 103(9):806-15. PubMed ID: 22727954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
    Sagi L; Zvulunov A; Lapidoth M; Ben Amitai D
    Dermatology; 2014; 228(2):136-44. PubMed ID: 24556822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
    Ahogo CK; Ezzedine K; Prey S; Colona V; Diallo A; Boralevi F; Taïeb A; Léauté-Labrèze C
    Br J Dermatol; 2013 Dec; 169(6):1252-6. PubMed ID: 23662995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.
    Xiao Q; Li Q; Zhang B; Yu W
    Pediatr Surg Int; 2013 Jun; 29(6):575-81. PubMed ID: 23519547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase.
    Vivas-Colmenares GV; Bernabeu-Wittel J; Alonso-Arroyo V; Matute de Cardenas JA; Fernandez-Pineda I
    Pediatr Dermatol; 2015; 32(3):348-52. PubMed ID: 25721095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical propranolol for treatment of superficial infantile hemangiomas.
    Xu G; Lv R; Zhao Z; Huo R
    J Am Acad Dermatol; 2012 Dec; 67(6):1210-3. PubMed ID: 22516113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.
    Georgountzou A; Karavitakis E; Klimentopoulou A; Xaidara A; Kakourou T
    Acta Paediatr; 2012 Oct; 101(10):e469-74. PubMed ID: 22804809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infantile hemangiomas: what have we learned from propranolol?
    Hagen R; Ghareeb E; Jalali O; Zinn Z
    Curr Opin Pediatr; 2018 Aug; 30(4):499-504. PubMed ID: 29846253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequelae following infantile haemangiomas treated with propranolol.
    Baselga E; El Hachem M; Diociaiuti A; Carnevale C; Downey C; Roe E; Mascaro P; Neri I; Leuzzi M; Bernabeu-Wittel J; Monserrat-García MT; Ortiz-Prieto A; Torrelo A; Knopfel N; Vercellino N; Manunza F; Oranges T; Bassi A; Gonzalez-Enseñat MA; Vicente A; Gich I; Puig L
    Eur J Dermatol; 2021 Dec; 31(6):785-790. PubMed ID: 35107070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study.
    Zvulunov A; McCuaig C; Frieden IJ; Mancini AJ; Puttgen KB; Dohil M; Fischer G; Powell J; Cohen B; Ben Amitai D
    Pediatr Dermatol; 2011; 28(2):94-8. PubMed ID: 21362031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment.
    Petrovic J; Trifunovic B; Vukomanovic G; Topalovic M; Trajkovic G; Parezanović V
    J Dermatolog Treat; 2017 Sep; 28(6):554-558. PubMed ID: 28043186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and treatment of periorbital infantile hemangiomas: Case series and literature review.
    Sun LM; Xu Y; Xu MN; Wang M; Su Y; Yuan SM
    Int J Pediatr Otorhinolaryngol; 2020 Sep; 136():110157. PubMed ID: 32544638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol.
    Wu C; Guo L; Wang L; Li J; Wang C; Song D
    Medicine (Baltimore); 2019 Feb; 98(6):e14346. PubMed ID: 30732164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploration of the optimal time to discontinue propranolol treatment in infantile hemangiomas: A prospective study.
    Wang L; Wang W; Zhou Z; Li J; Li Z; Lv R; Xu G; Bi J; Huo R
    J Am Acad Dermatol; 2024 Apr; 90(4):783-789. PubMed ID: 38159645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.